Accenture May 25, 2021

RESEARCH REPORT

In brief

  • A new economic environment is demanding change for biopharma’s, especially as New Science grows in prominence.
  • New Science, the combo of advanced science and tech, is expected to drive 81 percent biopharma revenue growth, but is more expensive to develop.
  • What if biopharma companies could tie profitability to innovation, growth, and better patient outcomes made possible by New Science?
  • It’s time to rebalance the treatment-cost equation from old ways of operating to new ways of discovering, developing and commercializing treatments.
How do you lead amidst change?
A new economic environment is demanding change in biopharma. When a global pandemic forced the industry into unprecedented action, the...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

Continue Reading

 
Topics: Biotechnology, Pharma, Pharma / Biotech, Survey / Study, Trends
Related Articles:
Halozyme Pulls €2B Acquisition Bid as Evotec Commits to Standalone Strategy
More than half of US adults could benefit from GLP-1 medications, researchers find
RNA editing is the next frontier in gene therapy—here's what you need to know
Rand roadblock: Biotech bill’s uncertain future
How Digital Chemistry Will Improve Cross-Functional Collaboration In The Biopharma Industry

Share This Article